Triamterene
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Triamterene: From Oedema/Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Triamterene is a potassium-sparing diuretic conventionally used for fluid retention (oedema) and hypertension. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction with no independent evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Oedema / hypertension (potassium-sparing diuretic class) — no South Africa-specific indication text available |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not retrievable from DrugBank at the time of this report (flagged as a High-severity data gap). Based on known pharmacology, triamterene is a potassium-sparing diuretic that blocks the epithelial sodium channel (ENaC) in the distal nephron, reducing sodium reabsorption and potassium excretion — its established use is chronic oral management of oedema and hypertension.
Malignant renovascular hypertension, however, is a hypertensive emergency typically driven by severe renin-angiotensin-aldosterone system (RAAS) activation, and standard management relies on intravenous antihypertensives and urgent correction of the underlying renal vascular lesion — not chronic oral diuretics. The evidence pack’s own mechanistic assessment flags a specific safety concern: in a high-renin state such as this, a potassium-sparing agent carries a meaningful hyperkalaemia risk rather than a clear therapeutic benefit.
The identical prediction score assigned to a closely related disease node (“malignant hypertensive renal disease,” rank 2) with the same lack of supporting evidence suggests these two high-ranking predictions likely reflect similarity between disease embeddings in the knowledge graph rather than an independently validated pharmacological signal. This prediction should be treated as hypothesis-generating only, not as clinical guidance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Triamterene is not currently marketed in South Africa — no SAHPRA registrations were found (0 licenses on record). No product, dosage form, or approved indication data is available for this evaluation.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: TFDA/PI warnings and contraindications for this drug are currently a Blocking data gap (DG001) — this alone prevents progression to a formal safety (S1) review.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but evidence level is L5 — no clinical trials, no supporting literature, and the drug is unregistered in South Africa. The rationale itself raises a plausible safety concern (hyperkalaemia risk in a high-renin hypertensive emergency) rather than supporting the prediction, and the same score applied to a near-duplicate disease node suggests a knowledge-graph artefact rather than an independent signal.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Independent preclinical or clinical evidence specific to malignant renovascular hypertension (or the related renal disease indication)
- Clinical assessment of whether a chronic oral potassium-sparing diuretic is even an appropriate drug class for a hypertensive emergency indication
- SAHPRA registration status confirmation, since the product is not currently marketed in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.